“abbie-celniker” Archives

in
Entry Author Date Location
SPECIAL REPORT: 2019 Biopharma Outlook – Facing an Uncertain Future 03/01/19 National
Xconomy Awards 2018 Gala Honors the Best of Boston Life Science: Slideshow 10/11/18 Boston
The Winners of the 2018 Xconomy Awards Are… 09/05/18 Boston
Inclusion in Labs, the C-Suite & More: Xconomy Awards Diversity Finalists 08/09/18 Boston
The 2018 Xconomy Awards Finalists Are… 06/28/18 Boston
Rheos Medicines Launches, Backed by $60M for Immunometabolism R&D 03/22/18 Boston
Check Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today 04/06/17 Boston
Goldfinch Bio Aims $55M and Cancer Strategy at Genetic Kidney Disease 12/14/16 Boston
Third Rock Gets $616M to Grow New Crop of Biotech Startups 10/31/16 Boston
Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer 09/21/16 Boston
Eleven Bio’s Eye Disease Drug Set For $22.5M Milestone from Roche 07/08/16 Boston
Eleven Bio, Still Breathing, Sells Eye Drug to Roche 06/13/16 Boston
With Second Eye Drug Flop, Eleven Heads Back to Drawing Board 01/19/16 Boston
Eleven Bio’s Shares Routed as Dry Eye Drug Flunks Phase 3 Test 05/18/15 Boston
Eleven Prices IPO Below Projected Range, Grabs $50M 02/06/14 Boston
Eleven’s Hybrid Approach Takes Shape With ThromboGenics Pact 05/29/13 Boston
Abbott’s Humira, the 3rd-in-Class Drug That Toppled Lipitor as No. 1 04/16/12 National
The Genetics Institute Impact: Caught on Video 12/20/11 Boston
Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” on Dec. 14 10/21/11 Boston
The Genetics Institute Impact: Join Mark Ptashne, Tom Maniatis & Gabe Schmergel on Dec. 14 10/11/11 Boston
Tokai Gets $23M, Eleven Therapeutics Hires New CEO, Ariad Drug Advances, & More Boston-Area Life Sciences News 09/23/11 Boston
Eleven Biotherapeutics Dials Up New CEO, Primes Lead Eye Drug for Clinic Next Year 09/22/11 Boston
Alexion Pharma Gobbles Up Taligen in $111M Buyout 01/31/11 Boston
Taligen Collects $10M For Focus on Rare Diseases 08/23/10 Boston
Bicoastal Brain Scramble? Company Cultures Boiled Down to One Word, Part 2—Boston vs. Seattle 09/03/09 Boston
Taligen Raises $26M For Inflammation Drugs 05/12/09 Boston
Dyax and Vertex Drugs Move Toward Market, Taligen Moves to MA, Covidien Moves Into Venture Territory, & More Life Sciences News 08/20/08 Boston
Taligen CEO Aims to Develop Drugs For Inflammatory Diseases, Build Company in Cambridge 08/14/08 Boston
Page 1 of 1